Oct 05, 2017
Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Sep 15, 2017
New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes
Sep 08, 2017
Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma
Aug 29, 2017
New Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With History Of Stroke
Aug 29, 2017
New Virtual Histology Sub-Study Evaluates Impact Of Repatha® (Evolocumab) On Coronary Artery Plaque Composition
Aug 28, 2017
New Repatha® (evolocumab) Analysis Demonstrates Cardiovascular Outcomes Efficacy And Safety Of Achieving Very Low LDL-C Levels
Aug 25, 2017
Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017
Aug 23, 2017
New Economic Analysis Based On Repatha® (Evolocumab) Outcomes Data Published In JAMA Cardiology
Aug 21, 2017
Amgen To Present New Data From The Repatha® (Evolocumab) Cardiovascular Outcomes Study At ESC Congress 2017
Aug 16, 2017
Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine
Jul 27, 2017
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
Jul 21, 2017
Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Jun 11, 2017
Medication That Inhibits PCSK9 Safely Reduces Cardiovascular Risk in Patients with Type 2 Diabetes
Jun 05, 2017
Amgen Submits Regulatory Applications For Repatha® (evolocumab) Cardiovascular Outcomes Data In US And Europe
Jun 04, 2017
Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 04, 2017
Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting